Evidence map›Paper›PMID 40794434›Full record

ArticleThe Journal of clinical investigation2025

The NaV1.5 auxiliary subunit FGF13 modulates channels by regulating membrane cholesterol independent of channel binding.

Aravind R Gade, Mattia Malvezzi, Lala Tanmoy Das, Maiko Matsui, Cheng-I J Ma, Keon Mazdisnian, Steven O Marx, Frederick R Maxfield, Geoffrey S Pitt

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Aravind R GadeCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.
Mattia MalvezziCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.
Lala Tanmoy DasCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.
Maiko MatsuiCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.
Cheng-I J MaDepartment of Biochemistry, Weill Cornell Medicine, New York, New York, USA.
Keon MazdisnianCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.
Steven O MarxDivision of Cardiology, Department of Medicine, and Department of Pharmacology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Frederick R MaxfieldDepartment of Biochemistry, Weill Cornell Medicine, New York, New York, USA.
Geoffrey S PittCardiovascular Research Institute, Weill Cornell Medicine, New York, New York, USA.

Funding

Weill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6M
Phosphorylation-dependent regulation of calcium channels by macromolecular complexesR01HL146149 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Steven O Marx, Geoffrey S Pitt · 2019 to 2026
$5.0M
Investigating Cardiac Ion Channels by Novel MethodsR01HL155377 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Steven O Marx · 2021 to 2026
$3.8M
Dynamic changes of the Nav1.5 interactome and contributions to heart failureR01HL160089 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARX, STEVEN O, PITT, GEOFFREY S · 2021 to 2024
$2.7M
Mechanistic re-evaluation of fibroblast growth factor homologous factors in the heartR01HL177538 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Steven O Marx, Geoffrey S Pitt · 2025 to 2026
$1.4M
NHLBI NIH HHS R01 HL146149NHLBI NIH HHS R01 HL155377NHLBI NIH HHS R01 HL160089NHLBI NIH HHS R01 HL177538NIGMS NIH HHS T32 GM152349
6 · The paper itself

Abstract

Fibroblast growth factor homologous factors (FHFs) bind to the cytoplasmic C-terminus of voltage-gated sodium channels (VGSCs) and modulate channel function. Variants in FHFs or VGSCs perturbing that bimolecular interaction are associated with arrhythmias. Like some channel auxiliary subunits, FHFs exert additional cellular regulatory roles, but whether these alternative roles affect VGSC regulation is unknown. Using a separation-of-function strategy, we show that a structurally guided, binding-incompetent, mutant fibroblast growth factor 13 (FGF13; the major FHF in mouse heart), confers complete regulation of VGSC steady-state inactivation (SSI), the canonical effect of FHFs. In cardiomyocytes isolated from Fgf13-KO mice, expression of the mutant FGF13 completely restores WT regulation of SSI. FGF13 regulation of SSI derives from effects on local accessible membrane cholesterol, which is unexpectedly polarized and concentrated in cardiomyocytes at the intercalated disc (ID), where most VGSCs localize. Fgf13-KO eliminates the polarized cholesterol distribution and causes loss of VGSCs from the ID. Moreover, we show that the previously described FGF13-dependent stabilization of VGSC currents at elevated temperatures depends on the cholesterol mechanism. These results provide new insights into how FHFs affect VGSCs and alter the canonical model by which channel auxiliary subunits exert influence.

Indexed as

Cell MembraneCholesterolFibroblast Growth FactorsMyocytes, CardiacNAV1.5 Voltage-Gated Sodium ChannelAnimalsHEK293 CellsHumansMiceMice, KnockoutCholesterolfibroblast growth factor 13Fibroblast Growth FactorsNAV1.5 Voltage-Gated Sodium ChannelScn5a protein, mouseCardiologyCholesterolIon channelsNeuroscienceSodium channels

Identifiers

PMID40794434
PMCPMC12520690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.